Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

Froude JW, Herbert AS, Pelat T, Miethe S, Zak SE, Brannan JM, Bakken RR, Steiner AR, Yin G, Hallam TJ, Sato AK, Hust M, Thullier P, Dye JM.

Viruses. 2018 May 26;10(6). pii: E286. doi: 10.3390/v10060286.

2.

The European AntibotABE Framework Program and Its Update: Development of Innovative Botulinum Antibodies.

Rasetti-Escargueil C, Avril A, Miethe S, Mazuet C, Derman Y, Selby K, Thullier P, Pelat T, Urbain R, Fontayne A, Korkeala H, Sesardic D, Hust M, Popoff MR.

Toxins (Basel). 2017 Oct 2;9(10). pii: E309. doi: 10.3390/toxins9100309. Review.

3.

Generation and characterization of protective antibodies to Marburg virus.

Froude JW, Pelat T, Miethe S, Zak SE, Wec AZ, Chandran K, Brannan JM, Bakken RR, Hust M, Thullier P, Dye JM.

MAbs. 2017 May/Jun;9(4):696-703. doi: 10.1080/19420862.2017.1299848. Epub 2017 Mar 13.

4.

Neutralization of Botulinum Neurotoxin Type E by a Humanized Antibody.

Derman Y, Selby K, Miethe S, Frenzel A, Liu Y, Rasetti-Escargueil C, Avril A, Pelat T, Urbain R, Fontayne A, Thullier P, Sesardic D, Lindström M, Hust M, Korkeala H.

Toxins (Basel). 2016 Sep 12;8(9). pii: E257. doi: 10.3390/toxins8090257.

5.

Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.

Miethe S, Mazuet C, Liu Y, Tierney R, Rasetti-Escargueil C, Avril A, Frenzel A, Thullier P, Pelat T, Urbain R, Fontayne A, Sesardic D, Hust M, Popoff MR.

PLoS One. 2016 Aug 25;11(8):e0161446. doi: 10.1371/journal.pone.0161446. eCollection 2016.

6.

Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin.

Respaud R, Marchand D, Pelat T, Tchou-Wong KM, Roy CJ, Parent C, Cabrera M, Guillemain J, Mac Loughlin R, Levacher E, Fontayne A, Douziech-Eyrolles L, Junqua-Moullet A, Guilleminault L, Thullier P, Guillot-Combe E, Vecellio L, Heuzé-Vourc'h N.

J Control Release. 2016 Jul 28;234:21-32. doi: 10.1016/j.jconrel.2016.05.018. Epub 2016 May 9.

PMID:
27173943
7.

Development of Human-Like scFv-Fc Neutralizing Botulinum Neurotoxin E.

Miethe S, Rasetti-Escargueil C, Avril A, Liu Y, Chahboun S, Korkeala H, Mazuet C, Popoff MR, Pelat T, Thullier P, Sesardic D, Hust M.

PLoS One. 2015 Oct 6;10(10):e0139905. doi: 10.1371/journal.pone.0139905. eCollection 2015.

8.

Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.

Avril A, Miethe S, Popoff MR, Mazuet C, Chahboun S, Rasetti-Escargueil C, Sesardic D, Thullier P, Hust M, Pelat T.

BMC Biotechnol. 2015 Sep 17;15:86. doi: 10.1186/s12896-015-0206-0.

9.

Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.

Rasetti-Escargueil C, Avril A, Chahboun S, Tierney R, Bak N, Miethe S, Mazuet C, Popoff MR, Thullier P, Hust M, Pelat T, Sesardic D.

MAbs. 2015;7(6):1161-77. doi: 10.1080/19420862.2015.1082016. Epub 2015 Sep 18.

10.

Structural differences of amyloid-β fibrils revealed by antibodies from phage display.

Droste P, Frenzel A, Steinwand M, Pelat T, Thullier P, Hust M, Lashuel H, Dübel S.

BMC Biotechnol. 2015 Jun 18;15:57. doi: 10.1186/s12896-015-0146-8.

11.

Effect of formulation on the stability and aerosol performance of a nebulized antibody.

Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille JF, Viaud-Massuard MC, Diot P, Si-Tahar M, Vecellio L, Heuzé-Vourc'h N.

MAbs. 2014;6(5):1347-55. doi: 10.4161/mabs.29938. Epub 2014 Oct 30.

12.

Detection of antiranibizumab antibodies among patients with exudative age-related macular degeneration.

Leveziel N, Pelat T, Watier H, Thullier P, Souied EH.

Ophthalmologica. 2014;232(1):53-6. doi: 10.1159/000360186. Epub 2014 May 20.

PMID:
24854579
13.

Human-like antibodies neutralizing Western equine encephalitis virus.

Hülseweh B, Rülker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, Dübel S, Thullier P, Hust M.

MAbs. 2014 May-Jun;6(3):718-27. doi: 10.4161/mabs.28170. Epub 2014 Feb 11.

14.

Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D, Hust M.

MAbs. 2014 Mar-Apr;6(2):446-59. doi: 10.4161/mabs.27773. Epub 2014 Jan 9.

15.

Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.

Thullier P, Avril A, Mathieu J, Behrens CK, Pellequer JL, Pelat T.

PLoS One. 2013 May 31;8(5):e65855. doi: 10.1371/journal.pone.0065855. Print 2013.

16.

Isolation of antibodies from non-human primates for clinical use.

Avril A, Froude JW, Mathieu J, Pelat T, Thullier P.

Curr Drug Discov Technol. 2014 Mar;11(1):20-7. Review.

PMID:
23410051
17.

Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.

Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall HJ, Hust M, Hülseweh B.

PLoS One. 2012;7(5):e37242. doi: 10.1371/journal.pone.0037242. Epub 2012 May 30.

18.

Antibodies against anthrax: mechanisms of action and clinical applications.

Froude JW 2nd, Thullier P, Pelat T.

Toxins (Basel). 2011 Nov;3(11):1433-52. doi: 10.3390/toxins3111433. Epub 2011 Nov 16. Review.

19.

Antibodies for biodefense.

Froude JW, Stiles B, Pelat T, Thullier P.

MAbs. 2011 Nov-Dec;3(6):517-27. doi: 10.4161/mabs.3.6.17621. Epub 2011 Nov 1. Review.

20.

Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin.

Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RG, Sesardic D, Thullier P.

BMC Biotechnol. 2011 Nov 23;11:113. doi: 10.1186/1472-6750-11-113.

Supplemental Content

Loading ...
Support Center